| 1 |
What is the primary function of AI in the medical imaging industry?
|
To improve diagnostic accuracy and patient outcomes |
|
AI in medical imaging primarily helps analyze images more accurately and quickly, aiding radiologists in diagnosing diseases and improving patient care. |
AI algorithms can detect patterns and anomalies that may be missed by humans. This leads to faster and more precise diagnoses. To name a few positives, Cost reduction, administration, marketing, or research are secondary and any indirect benefits. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 2 |
Which of the following is a key benefit of AI in radiology noted in the article?
|
|
|
AI systems assist radiologists by providing an additional, objective analysis of medical images, helping confirm or question initial diagnoses. |
AI acts as a diagnostic support tool, not a replacement. It generally improves speed and accuracy rather than reducing speed. Scheduling or cost increases are not primary benefits highlighted. The need for radiologists is not increased; AI complements their work in a way which doesn't replace or disregard the original opinion/diagnosis. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 3 |
What does AI literacy refer to according to the article?
|
Understanding and knowledge of AI technology |
|
AI literacy involves being informed about how AI works, its applications, benefits, and limitations, enabling users and professionals to effectively interact with AI tools. |
It’s about comprehension and critical thinking regarding AI, not technical repair or legal/financial specifics. Increasing AI literacy supports better adoption and responsible use for everyone involved. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 4 |
Which factor is NOT listed as influencing the acceptability of AI among healthcare professionals?
|
The color of the AI machines |
|
The color of AI machines has no relevance to how healthcare professionals evaluate or accept AI in their work environments. |
Acceptability of AI is influenced by trust, understanding, how well it integrates with current systems, and how open professionals are to using new technology. Aesthetic features like color are not mentioned as meaningful factors in professional decision-making. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 5 |
What role does social influence play in AI acceptability in healthcare according to the article?
|
Affects healthcare professionals’ decisions to use AI |
|
Social influence, such as opinions from colleagues, institutional culture, or professional communities, can strongly shape whether healthcare professionals are open to adopting AI technologies.
|
The Technology Acceptance Model (TAM) and similar frameworks recognize social influence as a major factor in technology adoption. It does not determine budgets, marketing, or technical performance like diagnostic accuracy. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 6 |
What is a perceived threat regarding AI usage in healthcare settings?
|
Concerns about replacing healthcare professionals |
|
One of the most commonly reported concerns is that AI might replace human roles, particularly in diagnostics and decision-making, leading to fear and resistance among healthcare workers. |
This perceived threat to job security can reduce trust and slow adoption. While AI may change workflows, it's generally designed to assist, not replace. The other options (IT workload, space, patient interaction) are secondary or less emphasized concerns. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 7 |
According to the article, what is essential for increasing AI acceptability among medical professionals?
|
Designing human-centred AI systems |
|
The article emphasizes that AI must be designed with users—medical professionals—in mind, making the technology intuitive, supportive, and aligned with clinical workflows to boost trust and acceptability. |
Human-centred design ensures usability, relevance, and ethical integration, which are critical for adoption. High algorithmic performance is important, but not sufficient on its own. Cost and promotion help but aren’t as central to user acceptability. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 8 |
What does the 'system usage' category of AI acceptability factors include according to the article?
|
Factors like value proposition and integration with workflows |
|
The 'system usage' category focuses on how AI fits into the actual clinical environment, including how valuable it is perceived to be (value proposition) and how smoothly it integrates with existing workflows and practices. |
According to the article and related frameworks (like the Unified Theory of Acceptance and Use of Technology), practical aspects of system usage, not personal preferences or demographics are key to AI acceptability. Geographic location, insurance type, or provider age aren’t part of this category. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 9 |
How does ethicality impact AI acceptability among healthcare professionals?
|
Affects views on AI based on compatibility with professional values |
|
Ethicality in this context refers to whether AI systems align with healthcare professionals’ moral principles and professional duties, such as patient safety, autonomy, and fairness. If AI tools conflict with those values, they’re less likely to be accepted. |
Ethical alignment is a critical trust-building factor in healthcare. It’s not about pricing, manufacturing, or limited to legal concerns. Medical professionals are especially sensitive to ethical risks and implications of using AI in patient care. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 10 |
What methodological approach did the article emphasize for future AI acceptability studies?
|
Considering user experience and system integration deeply |
|
The article stresses that future studies on AI acceptability should prioritize how users interact with the system and how well AI integrates into existing clinical workflows both are key to real-world adoption. |
Human-centered design and implementation science emphasize these factors to ensure usability and clinician buy-in. Economic focus or limiting AI use to large hospitals overlooks broader and more impactful adoption barriers. Speed without accuracy is counterproductive in medical diagnostics. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 11 |
What is the primary objective of using human embryonic stem cells in treating Parkinson’s disease?
|
To replace lost dopamine neurons. |
|
Parkinson’s disease is primarily caused by the loss of dopamine-producing neurons in a region of the brain called the substantia nigra. Using human embryonic stem cells (hESCs) allows researchers to generate new dopamine neurons to replace those lost due to the disease. |
Stem cell therapy aims to restore normal dopamine levels and improve motor function. While neurogenesis and brain plasticity are relevant concepts, replacing the dopamine neurons is the main therapeutic target in Parkinson’s treatment using hESCs. Increasing brain size or general cognitive enhancement is not the focus here. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 12 |
Which animal was used to test the STEM-PD product for safety and efficacy?
|
Monkeys |
|
The STEM-PD product, which uses human embryonic stem cell-derived dopamine neurons, was tested on monkeys to evaluate its safety and efficacy before human clinical trials. Non-human primates are often used in neurological studies because of their close similarity to humans in brain structure and function. |
Monkeys provide a reliable model for Parkinson’s disease, allowing researchers to assess how well the transplanted neurons survive and function. Rats and mice are commonly used for early-stage studies, but monkeys are preferred for complex neurological models like Parkinson’s before moving to human trials. Rabbits and pigs are not typically used for this specific type of neurodegenerative testing. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 13 |
What was the duration of the preclinical safety study in rats mentioned in the article?
|
9 months |
|
The article mentions a 9-month preclinical safety study conducted in rats to assess the long-term safety of the stem cell-derived product before moving on to further testing. |
Extended duration studies like 9 months help identify potential delayed adverse effects. Shorter or longer durations may not capture the full safety profile as comprehensively. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 14 |
What is the name of the clinical trial phase mentioned for STEM-PD?
|
|
|
The clinical trial for STEM-PD is described as a combined Phase I/IIa trial, which typically focuses on evaluating both safety (Phase I) and preliminary efficacy (Phase IIa) of the treatment. |
Early-phase trials often combine phases to accelerate the development process, especially for innovative therapies like stem cell treatments. Later phases (II, III, IV) focus on larger populations and longer-term effects. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 15 |
How is the STEM-PD product manufactured?
|
Under GMP-compliant conditions |
|
The STEM-PD product is manufactured under Good Manufacturing Practice (GMP)-compliant conditions, ensuring quality, safety, and regulatory standards for clinical-grade stem cell products. |
GMP compliance is mandatory for products intended for human clinical use to minimize risks of contamination and ensure reproducibility. Spontaneous differentiation, non-GMP, random integration, or skipping regulatory testing would pose significant safety and efficacy risks. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 16 |
According to the article, what confirmed the safety of the STEM-PD product in rats?
|
There were no adverse effects or tumor formation. |
|
The safety of the STEM-PD product in rats was confirmed because no adverse effects, including tumor formation, were observed during the preclinical safety study. |
Lack of tumor formation is crucial in stem cell therapies to ensure that transplanted cells do not become cancerous. No adverse immune reactions or biodistribution outside the brain also support safety. The other options indicate safety concerns or failures. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 17 |
What key finding was noted in the efficacy study of STEM-PD in rats?
|
Transplanted cells reversed motor deficits in rats. |
|
The efficacy study showed that the transplanted stem cell-derived dopamine neurons improved motor function in Parkinson’s disease model rats, demonstrating therapeutic potential. |
Improvement in motor symptoms is a key indicator of success in Parkinson’s treatments. The other options indicate failure or adverse outcomes, which were not reported. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 18 |
What specific markers were used to assess the purity of the STEM-PD batch?
|
GIRK2 and ALDH1A1 |
|
GIRK2 and ALDH1A1 are specific markers used to identify and confirm the presence of mature, functional dopamine neurons derived from stem cells, indicating the purity of the STEM-PD product batch. |
These markers are linked to substantia nigra dopamine neuron identity, crucial for Parkinson’s therapy. Other markers like OCT4 and NANOG are pluripotency markers (stemness), SOX1 and PAX6 are neural progenitor markers, and LMX1A/EN1 are developmental markers, but not the key purity markers cited. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 19 |
What role do growth factors like FGF8b and SHH play in the manufacturing process of STEM-PD?
|
They are used in cell patterning for specific neural fates. |
|
Growth factors like FGF8b (Fibroblast Growth Factor 8b) and SHH (Sonic Hedgehog) are critical during stem cell differentiation to guide cells toward becoming specific types of neurons, such as the dopamine neurons needed for Parkinson’s therapy. |
These factors mimic developmental signals that pattern the neural tube and specify ventral midbrain fate. They do not prevent differentiation or cause apoptosis but instead direct it toward desired neural lineages. Enhancing pluripotency is generally done by other factors. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 20 |
What was a key outcome measured in the preclinical trials for efficacy in rats?
|
Recovery of motor function |
|
The key outcome in preclinical trials for Parkinson’s models is typically the recovery or improvement of motor function, as Parkinson’s disease mainly affects movement. |
Improvement in motor symptoms demonstrates that the transplanted stem cells are functioning correctly. Other options like anxiety, cognition, lifespan, or brain size are less relevant primary endpoints for this therapy. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|